Quality Comes First

          

APAC MARKETS

We seek to advance highly specialised and scientifically valuable fields to elevate the standard of healthcare.

Discover more about Menarini Group

For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions.

Gain a single point of entry to all major APAC markets with a direct presence in 13 key markets.

Sharing your partnering idea

Leverage our omni-channel approach to grow your brand across Asia Pacific.

MARKETS

The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region.

As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.

Our APAC Headquarters

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

2013

2013

  • 2013 - 12 - 09

    Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia as First Clinical Development Candidate in $1 Billion Oncology Investment Alliance

    OXFORD, UK and BERLIN CHEMIE/MENARINI, GERMANY – 9th December 2013 – Oxford BioTherapeutics (OBT) and Berlin-Chemie (Menarini Group) announce today that they have designated a novel enhanced antibody targeting acute myeloid leukemia (AML) as the first clinical development candidate under the companies' strategic oncology collaboration. The companies have initiated formal regulatory enabling studies to support an application for a clinical phase I trial in AML patients in H2 2014.
  • 2013 - 11 - 02

    Menarini Asia-Pacific Announces Inauguration Of Menarini China HQ

    Singapore - 6 November 2013 – Menarini Asia-Pacific, a member of the world's largest Italian biopharmaceutical company, officially inaugurated the establishment of Menarini (China) Investment Co. Ltd. and the opening of its national headquarters on 29 October 2013 at the Wuhan National Bioindustry Base ("Wuhan Biolake") in Hubei Province, China. The auspicious ceremony was attended by 160 guests and officiated by Mr. Wang Yong Gao, Deputy Secretary of Hubei Provincial Party Committee, Mr. Dan Chang Chun, Executive Vice Director, Wuhan East Lake National High Tech Development Zone.
  • 2013 - 07 - 22

    Moberg Pharma and Menarini extend distribution agreement for Kerasal™ Nail to China

    Singapore - 22 July 2013 – Moberg Pharma AB (OMX: MOB) today announced that Menarini Asia-Pacific, a member of the Menarini Group – a top 40 global pharmaceutical company – has been granted the exclusive rights to market and sell Kerasal Nail® in China. The companies now intend to seek marketing authorization for the product in the Chinese market.
  • 2013 - 07 - 10

    Largest Regional Study of its kind reveals key insights into impact on quality of life of Chronic Skin Conditions

    Hong Kong - 11 July 2013 – For the many affected by chronic skin conditions such as atopic dermatitis and acne, the toll these conditions can take on them and their families is immeasurable. From managing unexpected flare ups to trying to conceal symptoms, skin disease can be an extensive source of physical, emotional and financial pain.
  • 2013 - 07 - 20

    Nobel Prize Laureatte, Dr. Louis J. Ignarro shares with Asian physicians key information about his breakthrough research in heart disease prevention

    Singapore - 20th June 2013 – Menarini Asia-Pacific, member of the world's largest Italian biopharmaceutical company, reaffirmed its commitment to improve the lives of people in the Asia-Pacific region with the visit of Prof. Louis J. Ignarro, a distinguished Nobel Prize winner, to share about his breakthrough research in heart disease prevention with Asian physicians. Prof. Ignarro was recently in Hong Kong and the Philippines to speak at the 44th Annual Convention of the Philippine Heart Association.
  • 2013 - 06 - 18

    MENARINI GROUP announces agreement with GILEAD SCIENCES to commercialize Ranexa® (ranolazine) in 50 new countries

    Florence, Italy - 18 June 2013 – Menarini Group, the leading Italian pharmaceutical company in the world, ranking 17th in Europe and 34th in the world (IMS World Review 2012) is pleased to announce the signing of an exclusive long-term agreement with Gilead Sciences, Inc. to commercialize Ranexa® (ranolazine), an antianginal agent, in 50 new countries including China, India, Australia and New Zealand.
  • 2013 - 05 - 27

    New Asia-Pacific Sexual Satisfaction Study Pulls Back the Covers on Relationship Tension Facing Couples

    Singapore - 28 May 2013 – One of the biggest ever surveys into sexual satisfaction in Asia-Pacific revealed today the intense levels of distress and frustration that premature ejaculation ("PE") causes men and their partners. Results showed the impact climax control has on relationships and why men and women are not seeking help.
  • 2013 - 03 - 21

    Premature ejaculation diminishes sexual satisfaction for many couples

    Singapore - 21 March 2013 – At the 28th Annual European Association of Urology (EAU) Congress in Milan, Europe's largest urology event with over 100 countries participating and over 14,000 visitors, healthcare professionals were urged to consider the impact of premature ejaculation (PE) on both men and their partners. During a symposium at the EAU Congress, sponsored by Menarini Group, entitled Premature ejaculation treatment: new perspectives for the couple, the following topics were discussed: PE as more than just a male sexual dysfunction, the diagnosis and treatment of PE in daily practice and the on-demand treatment of PE with dapoxetine.
  • 2013 - 03 - 03

    Menarini Asia-Pacific Highlights Social Consequences of Premature Ejaculation at 10th International Congress of Andrology

    Singapore - 28 February 2013 – Menarini Asia-Pacific, as part of leading international biopharmaceutical company, Menarini Group, participated at this year's International Congress of Andrology (ICA) in Melbourne, Australia, to raise awareness of one of the most common male sexual dysfunctions – Premature Ejaculation (PE). With PE affecting 30 per cent of men globally1 and 31 per cent of men in Asia Pacific2, this platform served as an opportunity to educate the community on the condition as well as the impact it has on a couple's sexual satisfaction.